


What is claimed is:

1. A compound according to formula (I)



wherein:

R₁ is H or (C₁₋₆)alkyl;

R₂ is aryl, (C₃₋₇)cycloalkyl, or heterocycle;

R₃ is $\begin{array}{c} R_7 \\ | \\ -C-R_8 \\ | \\ R_9 \end{array}$, $\begin{array}{c} R_{10} \\ | \\ -N-R_{11} \end{array}$, O-R₁₂, or S-R₁₂;

R₄ is phenyl or heterocycle;

- 15 R₅ is H or up to three substituents independently selected from the list consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, aryl, alkoxy, or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, alkylcarboxy, alkylcarboxyalkyl, haloalkyl, and amino or mono- or dialkylamino; or R₅ represents a bridging moiety which is arranged to bridge two adjacent ring atoms wherein the bridging moiety comprises alkyl or dioxyalkylene;

20 R₆ is absent or oxo;

R₇ is -OH or (C₁₋₆)alkyOH;

- 25 R₈ and R₉ are each independently H, (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, aryl, or heterocycle;

R₁₀ and R₁₁ together with the N atom form a heterocycle ring which is substituted by -OH, or -(C₁₋₆)alkylOH;

5 R₁₂ is H, (C₁₋₆)alkyl, aryl, or heterocycle; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R₁ is methyl.
- 10 3. A compound according to claim 1 wherein R₂ is (C₃₋₇)cycloalkyl.
4. A compound according to claim 1 wherein R₄ is 2- or 3-thiophene.
- 15 5. A compound according to claim 1 wherein R₇ is -OH or (C₁₋₆)alkylOH unsubstituted or substituted by one to three halo groups.
6. A compound according to claim 1 wherein R₉ is H and R₈ is H, unsubstituted C₍₃₋₇₎cycloalkyl, or (C₁₋₆)alkyl unsubstituted or substituted by one to five substituents selected from the group consisting of halo and -OH.
- 20 7. A compound according to claim 1 wherein R₁₀ and R₁₁ together with the N atom form pyrrolidine substituted by -OH or -(C₁₋₆)alkylOH or piperidine substituted by -OH or -(C₁₋₆)alkylOH.
- 25 8. A compound according to claim 1 which is:
3-[4-(2-Hydroxy-ethanoyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 30 3-[4-((S)-2-Hydroxy-propanoyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 35 3-[4-(2-Hydroxy-2-methyl-propanoyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 3-[4-((S)-2-Hydroxy-3-methyl-butanoyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;

- 3-[4-((S)-2-Cyclohexyl-2-hydroxy-ethanoyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 5 3-[4-[1-((R)-2-Hydroxymethyl-pyrrolidin-1-yl)-methanoyl]-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 3-[4-[1-((S)-2-Hydroxymethyl-pyrrolidin-1-yl)-methanoyl]-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 10 3-[4-[1-(4-Hydroxy-piperidin-1-yl)-methanoyl]-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 2-Thiophen-2-yl-3-[4-(3,3,3-trifluoro-2-hydroxy-2-methyl-propanoyl)-piperazin-1-ylmethyl]-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 15 2-Thiophen-2-yl-3-[4-(3,3,3-trifluoro-2-hydroxy-propanoyl)-piperazin-1-ylmethyl]-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 20 2-Thiophen-2-yl-3-[4-(4,4,4-trifluoro-3-hydroxy-3-methyl-butanoyl)-piperazin-1-ylmethyl]-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
- 2-Thiophen-2-yl-3-[4-(4,4,4-trifluoro-3-hydroxy-butanoyl)-piperazin-1-ylmethyl]-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide; or
- 25 3-[4-((S)-2-Hydroxy-propanoyl)-2-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide; or a pharmaceutically acceptable salt thereof.
- 30 9. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.
10. A method for the treatment of the Primary and Secondary conditions in mammals, particularly humans, which comprises administering to a subject in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- 35

11. A method for the treatment of respiratory diseases in mammals, which comprises administering, to a subject in need of such treatment, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof.